CD22 positive B-cell acute lymphoblastic leukemia

CD22-positive B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled clonal proliferation and accumulation of immature B-cell precursor lymphoblasts in the bone marrow and peripheral blood

CD22-positive B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled clonal proliferation and accumulation of immature B-cell precursor lymphoblasts in the bone marrow and peripheral blood The condition predominantly affects the hematopoietic and lymphoid systems in pediatric and adult populations, leading to progressive bone marrow failure that clinically manifests as anemia, thrombocytopenia, and neutropenia Blasts may also infiltrate extr...

CD22-positive B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled clonal proliferation and accumulation of immature B-cell precursor lymphoblasts in the bone marrow and peripheral blood

The condition predominantly affects the hematopoietic and lymphoid systems in pediatric and adult populations, leading to progressive bone marrow failure that clinically manifests as anemia, thrombocytopenia, and neutropenia Blasts may also infiltrate extramedullary compartments, including the central nervous system, liver, spleen, and lymph nodes

Pathophysiologically, the leukemic blasts aberrantly express CD22, a transmembrane sialoglycoprotein receptor specific to the B-cell lineage that functions in immune regulation and serves as a key biomarker for targeted immunotherapies

Pathophysiologically, the leukemic blasts aberrantly express CD22, a transmembrane sialoglycoprotein receptor specific to the B-cell lineage that functions in immune regulation and serves as a key biomarker for targeted immunotherapies